1-3 of 3
Thomas Stromberg, PhD
Close
Sort by
Journal Articles

Selective Inhibition of Glycogen Synthase Kinase-3 by Facilitators of Insulin Response Promotes Proliferation and Survival in Multiple Myeloma Cells.

Helena Jernberg-Wiklund, PhD, Thomas Stromberg, PhD, Anna Hammarberg, Patrik Georgii-Hemming, MD, PhD, Anders Osterborg, MD, PhD, Kenneth Nilsson, MD, PhD
Journal: Blood
Blood (2007) 110 (11): 4789.
https://doi.org/10.1182/blood.V110.11.4789.4789
Published: 2007
Journal Articles

Targeting the Insulin-Like Growth Factor-I Receptor (IGF-IR) in Multiple Myeloma Cells Using Selective IGF-IR Tyrosine Kinase Inhibitors.

Thomas Stromberg, PhD, Simon Ekman, MD, PhD, Leonard Girnita, PhD, Johan Lennartsson, Ulf Hellman, PhD, Kristina Carlson, MD, PhD, Anders Osterborg, MD, PhD, Karin Vanderkerken, PhD, Magnus Axelson, MD, PhD, Olle Larsson, MD, PhD, Kenneth Nilsson, MD, PhD, Helena Jernberg-Wiklund, PhD
Journal: Blood
Blood (2004) 104 (11): 639.
https://doi.org/10.1182/blood.V104.11.639.639
Published: 2004
Journal Articles

Inhibiting the IGF-1 Receptor Tyrosine Kinase with Picropodophillin: An In Vitro and In Vivo Study in the 5T33MM Mouse Model.

Karin Vanderkerken, PhD, Eline Menu, Thomas Stromberg, PhD, Hendrik De Raeve, MD, Kewal Asosingh, PhD, Ben Van Camp, MD, PhD, Helena Jernberg-Wiklund, PhD
Journal: Blood
Blood (2004) 104 (11): 640.
https://doi.org/10.1182/blood.V104.11.640.640
Published: 2004